FibroGen, Inc.

NASDAQ:FGEN

$0.4632 USD

-$0.01 (-2.61%)

Volume
607.64K
Average Volume
1.32M
Market Capitalization
$46.68M
P/E Ratio
-0.38
Dividend Yield
0.00%
Price Target
$28.00
Year High
$2.93
Year Low
$0.18
Payout Ratio
$0.00
Current Ratio
$1.28

Industry, Sector & symbol

Stock Exchange NASDAQ Global Select
CEO Mr. Thane Wettig
Industry Biotechnology
Sector Healthcare
Current Symbol FGEN
CUSIP 31572Q808
CIK 0000921299
Web https://www.fibrogen.com
Phone 415 978 1200
Currency USD
Employees 486
Country US

Liquidity

Debt-to-Equity Ratio -0.39
Payout Ratio 0.00
Current Ratio 1.28
Quick Ratio 1.16
Cash Ratio 0.69

Sales & Book Value

Annual Sales $147.75M
Price / Sales 0.26
Cash Flow -1.26
Price / Cash Flow -0.37
Price / Book -0.23

Price Target and Rating

Average Stock Price Forecast $28.00
High Stock Price Forecast $28.00
Low Stock Price Forecast $28.00
Forecast Upside/Downside -98.35%
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 2 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-2.92
Trailing P/E Ratio -0.38
PEG Ratio -0.01
P/E Growth -0.01
Net Income $-284.23M
Net Margin -67.66%
Pretax Margin -69.56%
Return on Equity 56.23%
Return on Assets -46.06%

Financials Score

AltmanZ Score -10.41
Piotroski Score 1.00
Working Capital 54M
Total Assets 264.42M
Ebit -104.09M
Market Cap 47.93M
Total Liabilities 466.12M

Poll Results

About FibroGen, Inc. (NASDAQ:FGEN) Stock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Ph ... ase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FibroGen Appoints David DeLucia as Chief Financial Officer

2024-12-16 08:05:00

SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024.

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

2024-11-12 20:38:05

FibroGen, Inc. (NASDAQ:FGEN ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A & IR Thane Wettig - CEO Juan Graham - CFO Conference Call Participants Andy Hsieh - William Blair Operator Good day and welcome to the FibroGen Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates

2024-11-12 19:15:55

FibroGen (FGEN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.52 per share a year ago.

FibroGen Reports Third Quarter 2024 Financial Results

2024-11-12 16:05:00

SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company's recent developments.

FibroGen to Report Third Quarter 2024 Financial Results

2024-11-04 16:05:00

SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Frequently Asked Questions

What is the current FibroGen, Inc. (FGEN) stock price?

FibroGen, Inc.(NASDAQ:FGEN) stock price is $0.4632 in the last trading session. During the trading session, FGEN stock reached the peak price of $2.93 while $0.18 was the lowest point it dropped to. The percentage change in FGEN stock occurred in the recent session was --2.61% while the dollar amount for the price change in FGEN stock was -$-0.01.

FGEN's industry and sector of operation?

The NASDAQ listed FGEN is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of FGEN?

Ms. Christine L. Chung | Senior Vice President of China Operations
Ms. Tricia Stewart | Chief People Officer
Dr. Barry A. Berkowitz Ph.D. | Founder
Mr. Kirk A. Christoffersen MBA | Chief Business Officer
David DeLucia | Vice President of Corporate FP&A and Investor Relations

How many employees does FGEN have?

Number of FGEN employees currently stands at 486. FGEN operates from 409 Illinois Street, San Francisco, CA 94158, US.

Link for FGEN official website?

Official Website of FGEN is: https://www.fibrogen.com

How do I contact FGEN?

FGEN could be contacted at phone #415 978 1200 and can also be accessed through its website. FGEN operates from 409 Illinois Street, San Francisco, CA 94158, US.

How many shares of FGEN are traded daily?

The average number of FGEN shares traded daily for last 3 months was 1.32M.

What is the market cap of FGEN currently?

The market value of FGEN currently stands at $46.68M with its latest stock price at $0.4632